Good Just Isn’t Good Enough For Aphria Stock

Good Just Isn’t Good Enough For Aphria Stock  | Oct 20, 2020 06:09

Could opportunity lie in the space between reality and expectations? That is the question those who are still willing to bet on the cannabis sector are asking in the wake of last week’s earnings report from Aphria (NASDAQ:APHA), (TSX:APHA).

The Ontario-based cannabis grower has watched its stock price sink since reporting its first-quarter earnings last Thursday. And here’s the rub: the stock slide comes despite fiscal results that show its sixth consecutive quarter of growth. In fact, Aphria hit a record in gross revenue, posting C$69.6 million (US$52.74), a jump of 23% compared to the previous quarter.

“Our financial results continue to be the envy of the industry,” Aphria’s chief finance officer Carl Merton reportedly said.

But those results were still not enough to meet analysts’ projections.

Aphria reported C$145.7 million (US$110.41) in net sales for its latest quarter, which ended Aug. 31, 4% below the previous three-month period. The company blamed this dip on a drop in sales in its prosperous German medicinal cannabis market.

The marijuana grower recorded at C$10-million (US$7.58) EBITDA, but analysts were looking for C$11.9 million (US$9.02) in earnings before interest, taxes, depreciation and amortization.

"Our strong first quarter results reflect the continued robust growth and development of Aphria's adult-use cannabis brands in Canada," chief executive officer Irwin Simon stated in a news release on Thursday.

Shares of Aphria fell more than 15% last Thursday, followed by another 2% loss on Friday to close at US$4.65 (C$6.13). The stock reversed the trend slightly yesterday, gaining 0.65% in the United States to close at US$4.68, and adding 0.82% in Canada to close at C$6.18. The stock is down about 2% in the last year.

Aphria Daily Chart

Aphria stock has done better than other Canadian-based pot stocks in the last quarter, gaining about 20%, which outpaced others like Canopy Growth (NYSE:CGC), which saw gains of less than 2% on its stock price, Aurora Cannabis (NYSE:ACB), which registered substantial 60%+ loss in stock price and Tilray (NASDAQ:TLRY), which took a 21% drubbing.

MedMen Continues On Downward Trend

MedMen Enterprises (OTC:MMNFF), (CSE:MMEN) shares hit a new all-time low last Friday after it reported its fourth-quarter results. The small U.S.-based marijuana company saw its revenues drop about 40% in the last quarter to US$27.4 million.

The reasons for the decline were vast, including shutdowns in some states, COVID-19-related declines and civil unrest in some U.S. markets.

To add insult to injury, analysts with Canaccord Genuity reduced the company’s price target to zero following the unveiling of the latest earnings report.

MedMen stock traded down again slightly yesterday to close at US$0.1213. The stock has lost more than 88.5% in the last year.

MedMen Weekly Char

Legalization In Canada Marks 2nd Anniversary

While market observers continue to speculate on when the U.S. will legalize marijuana, legalization marked its second anniversary in Canada this month.

Today, there are 507 licensed producers of weed in Canada, with about 60 of them selling into the recreational market.

One of the biggest issues facing growers in the Canadian market is oversupply, which means many companies could be facing tough decisions ahead: how big will the write-downs be?

This fall will also mark the first time cannabis grown outdoors will be hitting the market and adding to the supply.

Latest comments

Add a Comment
Please wait a minute before you try to comment again.
Write a reply...
Please wait a minute before you try to comment again.

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.

English (USA) English (UK) English (India) English (Australia) English (South Africa) English (Philippines) English (Nigeria) Deutsch Español (España) Español (México) Français Italiano Nederlands Português (Portugal) Polski Português (Brasil) Русский Türkçe ‏العربية‏ Ελληνικά Svenska Suomi עברית 日本語 한국어 简体中文 繁體中文 Bahasa Indonesia Bahasa Melayu ไทย Tiếng Việt हिंदी
Sign out
Are you sure you want to sign out?
Saving Changes


Download the App

Get free real time quotes, charts and alerts on stocks, indices, currencies, commodities and bonds. Get free top of the line technical analysis/predictors. is better on the App!

More content, faster quotes and charts, and a smoother experience is available only on the App.